Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. (Q51399602)

4 April 2018

title

Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. (English)

1 reference

4 April 2018

author name string

Olawale Osuntokun

1

1 reference

4 April 2018

Brian Millen

2

1 reference

4 April 2018

Wen I Xu

3

1 reference

4 April 2018

Ludmilla A Kryzhanovskaya

4

1 reference

4 April 2018

Carol Robertson-Plouch

5

1 reference

4 April 2018

Janice L Carlson

6

1 reference

4 April 2018

Nayan Acharya

7

1 reference

4 April 2018

Sara A Corya

8

1 reference

4 April 2018

language of work or name

English

0 references

publication date

24 May 2010

1 reference

4 April 2018

Journal of Psychopharmacology

published in

1 reference

4 April 2018

volume

25

1 reference

4 April 2018

issue

5

1 reference

4 April 2018

page(s)

630-638

1 reference

4 April 2018

Consensus development conference on antipsychotic drugs and obesity and diabetes

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110368872

21 January 2018

Identifiers

DOI

10.1177/0269881110368872

1 reference

4 April 2018

PubMed ID

20498135

1 reference

4 April 2018